The trial did not meet its primary objective to show superior efficacy of desvenlafaxine succinate sustained-release formulation compared to placebo. The company said that this is the first
BIND is a clinical-stage nanomedicine company that develops targeted and programmable therapeutics called Accurins. Following achievement of proof-of-concept, both the firms intend to expand the collaboration to develop
Last year, the company secured orphan drug designation from the US Food and Drug Administration (FDA) for Epidiolex to treat LGS. The company intends to report top-line data
The drug is approved for these children who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Earlier in 2008, the FDA approved Promacta for use in
The trial, being carrying out at MAC Clinical Research in Manchester, UK, will evaluate the safety and efficacy of oral ZPL-389 in the treatment of inflammatory skin diseases,
Results from the trial show that d-Methadone was generally well tolerated and a maximum tolerated dose (MTD) was achieved. The company said that the planned multiple ascending dose
The trial is being carried out at the University of Texas MD Anderson Cancer Center, Houston, Oncology Partners, Houston, and at UT Southwestern Medical Center, Dallas, Texas, US.
AATD is a rare genetic disease that severely damages the liver and lungs of affected children and adults. Currently, the company is conducting part B of a Phase
Currently, AG-120 is being evaluated in a Phase I clinical trial in patients with advanced hematologic malignancies that carry an IDH1 mutation. AML is characterized by rapid disease
The breakthrough therapy status is designed to expedite the development and review of medicines intended to treat serious diseases as well as help ensure patients have access to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.